אריקייס ליפוזומל 590 מג ישראל - עברית - Ministry of Health

אריקייס ליפוזומל 590 מג

truemed ltd, israel - amikacin as sulfate - תרחיף לשאיפה - amikacin as sulfate 70 mg/ml - amikacin

אמיקן ישראל - עברית - Ministry of Health

אמיקן

k.s.kim international (sk- pharma) ltd., israel - amikacin as sulfate - תמיסה להזרקה - amikacin as sulfate 250 mg / 1 ml - amikacin

אמיקצין-מדו ישראל - עברית - Ministry of Health

אמיקצין-מדו

a.l. medi-market ltd. - amikacin as sulfate - תמיסה להזרקה\אינפוזיה - amikacin as sulfate 250 mg / 1 ml - amikacin

אורלובין ישראל - עברית - Ministry of Health

אורלובין

a.l. medi-market ltd. - amikacin as sulfate - תמיסה להזרקה - amikacin as sulfate 250 mg / 1 ml - amikacin

אמיקצין ב.בראון 10 מגמל ישראל - עברית - Ministry of Health

אמיקצין ב.בראון 10 מגמל

lapidot medical import and marketing ltd - amikacin as sulfate - תמיסה לאינפוזיה - amikacin as sulfate 10 mg / 1 ml - amikacin

אמיקצין ב.בראון 5 מגמל ישראל - עברית - Ministry of Health

אמיקצין ב.בראון 5 מגמל

lapidot medical import and marketing ltd - amikacin as sulfate - תמיסה לאינפוזיה - amikacin as sulfate 5 mg / 1 ml - amikacin

אמיקצין - פרזניוס 100 מ"ג/2 מ"ל ישראל - עברית - Ministry of Health

אמיקצין - פרזניוס 100 מ"ג/2 מ"ל

medic trim healthcare ltd - amikacin as sulfate 100 mg / 2 ml - solution for injection - amikacin - treatment of serious nosocomial gram-negative bacillary and in some gram-positive infections in hospitals where resistance to gentamicin and tobramycin has been found

אמיקצין - פרזניוס 500 מ"ג/2 מ"ל ישראל - עברית - Ministry of Health

אמיקצין - פרזניוס 500 מ"ג/2 מ"ל

medic trim healthcare ltd - amikacin as sulfate 500 mg / 2 ml - solution for injection - amikacin - treatment of serious nosocomial gram-negative bacillary and in some gram-positive infections in hospitals where resistance to gentamicin and tobarmicin has been found

פרנטאל ישראל - עברית - Ministry of Health

פרנטאל

manon pharm ltd. - ascorbic acid; betacarotene; biotin; calcium carbonate; calcium pantothenate; chromium as chloride; colecalciferol; copper; cyanocobalamin; ferrous fumarate; folic acid; magnesium oxide; manganese as sulfate; nicotinamide; potassium iodide; pyridoxine (vit b6) hydrochloride; riboflavine; sodium molybdate; sodium selenate; thiamine (vit b1) mononitrate; tocopherol (vit e) (as tocopheryl acetate); vitamin a; zinc as oxide - טבליה - betacarotene 1500 iu; vitamin a 1500 iu; ascorbic acid 100 mg; folic acid 1 mg; riboflavine 3.4 mg; nicotinamide 20 mg; cyanocobalamin 12 mcg; colecalciferol 250 iu; biotin 30 mcg; copper 2 mg; sodium molybdate 25 mcg; manganese as sulfate 5 mg; zinc as oxide 25 mg; ferrous fumarate 60 mg; potassium iodide 0.15 mg; magnesium oxide 50 mg; chromium as chloride 25 mcg; calcium pantothenate 10 mg; pyridoxine (vit b6) hydrochloride 10 mg; thiamine (vit b1) mononitrate 3 mg; tocopherol (vit e) (as tocopheryl acetate) 30 iu; calcium carbonate 250 mg; sodium selenate 25 mcg - vitamin and mineral supplement for use during pregnancy and lactation.

פלויקס 75 מג ישראל - עברית - Ministry of Health

פלויקס 75 מג

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid